CytRx to Present at the 25th Annual ROTH Conference

  CytRx to Present at the 25th Annual ROTH Conference

25th Annual ROTH Conference

Business Wire

LOS ANGELES -- March 12, 2013

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, announced that President and CEO Steven A.
Kriegsman and Vice President of Business Development David J. Haen will
present at the 25^th Annual ROTH Conference on Tuesday, March 19, 2013, at
4:00 p.m. Pacific time (7:00 p.m. Eastern time). The conference is being held
at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.

A webcast of the presentation will be available on the Company’s website at
http://cytrx.com/investors/presentations.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company
specializing in oncology. The CytRx oncology pipeline includes two programs in
clinical development for cancer indications: aldoxorubicin (formerly known as
INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate
aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as
a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical
trial primarily in the same indication, and has initiated a Phase 1b
pharmacokinetics clinical trial in patients with metastatic solid tumors and a
Phase 1b study of aldoxorubicin in combination with doxorubicin in patients
with advanced solid tumors. The Company has held a positive meeting with the
FDA to discuss a potential Phase 3 pivotal trial with aldoxorubicin as a
therapy for patients with soft tissue sarcomas whose tumors have progressed
following treatment with chemotherapy, and has submitted a special protocol
assessment related to this trial. Tamibarotene is being tested in a
double-blind, placebo-controlled, international Phase 2b clinical trial in
patients with non-small-cell lung cancer. The Company reached its enrollment
target for that trial in February 2013. The Company completed its evaluation
of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in
high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a
partner for further development of bafetinib. For more information aboutCytRx
Corporation, visitwww.cytrx.com.

Contact:

Investor Relations
Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
twagner@legendsecuritiesinc.com
 
Press spacebar to pause and continue. Press esc to stop.